Barclays’s KalVista Pharmaceuticals KALV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Shares
Change %
Capital Flow Portfolio Weight Portfolio Position
2025
Q2
$1.91M Buy
168,923
+113,696
+206% +$1.29M ﹤0.01% 2263
2025
Q1
$638K Sell
55,227
-12,835
-19% -$148K ﹤0.01% 2700
2024
Q4
$577K Buy
68,062
+840
+1% +$7.12K ﹤0.01% 2967
2024
Q3
$778K Buy
67,222
+54,257
+418% +$628K ﹤0.01% 2761
2024
Q2
$152K Sell
12,965
-8,990
-41% -$105K ﹤0.01% 3185
2024
Q1
$260K Sell
21,955
-20,576
-48% -$244K ﹤0.01% 3203
2023
Q4
$521K Buy
42,531
+38,316
+909% +$469K ﹤0.01% 2971
2023
Q3
$40K Sell
4,215
-691
-14% -$6.56K ﹤0.01% 3681
2023
Q2
$44K Sell
4,906
-7,507
-60% -$67.3K ﹤0.01% 3730
2023
Q1
$97K Buy
12,413
+5,841
+89% +$45.6K ﹤0.01% 3548
2022
Q4
$45K Buy
6,572
+3,923
+148% +$26.9K ﹤0.01% 3809
2022
Q3
$38K Buy
2,649
+679
+34% +$9.74K ﹤0.01% 3737
2022
Q2
$19K Sell
1,970
-1,668
-46% -$16.1K ﹤0.01% 4116
2022
Q1
$54K Sell
3,638
-25,348
-87% -$376K ﹤0.01% 3976
2021
Q4
$383K Buy
28,986
+18,582
+179% +$246K ﹤0.01% 2625
2021
Q3
$181K Buy
10,404
+5,335
+105% +$92.8K ﹤0.01% 3023
2021
Q2
$122K Sell
5,069
-28,214
-85% -$679K ﹤0.01% 3074
2021
Q1
$854K Buy
33,283
+19,603
+143% +$503K ﹤0.01% 2381
2020
Q4
$260K Sell
13,680
-978
-7% -$18.6K ﹤0.01% 2596
2020
Q3
$185K Buy
14,658
+657
+5% +$8.29K ﹤0.01% 2775
2020
Q2
$169K Buy
14,001
+3,322
+31% +$40.1K ﹤0.01% 2887
2020
Q1
$82K Sell
10,679
-14,217
-57% -$109K ﹤0.01% 2901
2019
Q4
$444K Buy
24,896
+6,862
+38% +$122K ﹤0.01% 2753
2019
Q3
$209K Sell
18,034
-4,973
-22% -$57.6K ﹤0.01% 3037
2019
Q2
$510K Sell
23,007
-9,482
-29% -$210K ﹤0.01% 2706
2019
Q1
$930K Sell
32,489
-30,289
-48% -$867K ﹤0.01% 2193
2018
Q4
$1.24M Buy
62,778
+62,707
+88,320% +$1.24M ﹤0.01% 1679
2018
Q3
$2K Buy
+71
New +$2K ﹤0.01% 4175
2018
Q1
Sell
-1,349
Closed -$13K 4283
2017
Q4
$13K Buy
+1,349
New +$13K ﹤0.01% 3789
2016
Q3
Sell
-32
Closed 3998
2016
Q2
$0 Buy
+32
New ﹤0.01% 3727
2015
Q4
Sell
-5
Closed 3472
2015
Q3
$0 Sell
5
-12
-71% ﹤0.01% 4031
2015
Q2
$2K Buy
+17
New +$2K ﹤0.01% 3911